Brit J Cancer:SGK1抑制剂通过mTOR-Foxo3a信号通路诱导自我吞噬依赖的细胞凋亡

2017-08-26 AlexYang MedSci原创

尽管之前的研究表明SGK1抑制剂具有推迟癌症进展的作用,但是潜在的机制还没有被阐释。最近,有研究人员在人类前列腺癌(PCa)细胞系和PC3异种种植中调查了对GSK650394处理和SGK1沉默(或者超表达)后的细胞学响应。使用的技术包括流式细胞术、蛋白免疫印迹、免疫荧光和透射电子显微镜以及免疫组化技术。研究结果发现,SGK1抑制剂可以通过GSK650394或者SGK1 shRNA调节,来诱导G2/

尽管之前的研究表明SGK1抑制剂具有推迟癌症进展的作用,但是潜在的机制还没有被阐释。最近,有研究人员在人类前列腺癌(PCa)细胞系和PC3异种种植中调查了对GSK650394处理和SGK1沉默(或者超表达)后的细胞学响应。使用的技术包括流式细胞术、蛋白免疫印迹、免疫荧光和透射电子显微镜以及免疫组化技术。

研究结果发现,SGK1抑制剂可以通过GSK650394或者SGK1 shRNA调节,来诱导G2/M停止、细胞凋亡和细胞自噬。更进一步的是,3MA调控的细胞自噬抑制作用可以减弱SGK1抑制剂诱导的细胞凋亡,表明了细胞自噬的诱导可以领先于细胞凋亡。另外,SGK1的异位表达可以显著的减弱GSK650394诱导的作用。mTOR表达的抑制和Foxo3a的磷酸化对SGK1诱导的细胞自噬和细胞凋亡是非常关键的,并且至少部分通过pFoxo3a (S253)-LC3和pFoxo3a (S253)-p27互作来起作用。在前列腺癌细胞中,mTOR和SGK1的双重抑制作用增强了细胞自噬的激活并且导致了协同的杀伤细胞的作用。

最后,研究人员指出,他们的发现表明了SGK1抑制剂在体外和体内试验中展现出了显著的抗前列腺癌肿瘤活性。他们的研究阐释了一个新的前列腺癌中SGK1抑制剂作用机制,即可以通过mTOR-Foxo3a信号通路诱导细胞自噬依赖的细胞凋亡。

原始出处:

Weiwei Liu, Xuchu Wang, Zhenping Liu et al. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Brit J Cancer. 24 August 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2024539, encodeId=c2872024539cf, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 31 15:09:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851510, encodeId=81161851510f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 28 12:09:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340254, encodeId=6e9213402545c, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539625, encodeId=59c51539625c8, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237713, encodeId=5f5d23e713df, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Aug 27 13:29:37 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237385, encodeId=f37e23e385b3, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuNreCBwuEU9I5ich0uE1zdHnicdKjEibG64cgLHSp5sMMFMiatLiaDaSrGOj1jAaDuTZo7vDLDhgRFHt6/0, createdBy=caa52003923, createdName=狼毒花1982, createdTime=Sat Aug 26 13:15:28 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2018-05-31 hyf028
  2. [GetPortalCommentsPageByObjectIdResponse(id=2024539, encodeId=c2872024539cf, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 31 15:09:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851510, encodeId=81161851510f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 28 12:09:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340254, encodeId=6e9213402545c, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539625, encodeId=59c51539625c8, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237713, encodeId=5f5d23e713df, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Aug 27 13:29:37 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237385, encodeId=f37e23e385b3, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuNreCBwuEU9I5ich0uE1zdHnicdKjEibG64cgLHSp5sMMFMiatLiaDaSrGOj1jAaDuTZo7vDLDhgRFHt6/0, createdBy=caa52003923, createdName=狼毒花1982, createdTime=Sat Aug 26 13:15:28 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2017-10-28 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=2024539, encodeId=c2872024539cf, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 31 15:09:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851510, encodeId=81161851510f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 28 12:09:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340254, encodeId=6e9213402545c, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539625, encodeId=59c51539625c8, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237713, encodeId=5f5d23e713df, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Aug 27 13:29:37 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237385, encodeId=f37e23e385b3, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuNreCBwuEU9I5ich0uE1zdHnicdKjEibG64cgLHSp5sMMFMiatLiaDaSrGOj1jAaDuTZo7vDLDhgRFHt6/0, createdBy=caa52003923, createdName=狼毒花1982, createdTime=Sat Aug 26 13:15:28 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2024539, encodeId=c2872024539cf, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 31 15:09:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851510, encodeId=81161851510f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 28 12:09:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340254, encodeId=6e9213402545c, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539625, encodeId=59c51539625c8, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237713, encodeId=5f5d23e713df, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Aug 27 13:29:37 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237385, encodeId=f37e23e385b3, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuNreCBwuEU9I5ich0uE1zdHnicdKjEibG64cgLHSp5sMMFMiatLiaDaSrGOj1jAaDuTZo7vDLDhgRFHt6/0, createdBy=caa52003923, createdName=狼毒花1982, createdTime=Sat Aug 26 13:15:28 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2024539, encodeId=c2872024539cf, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 31 15:09:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851510, encodeId=81161851510f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 28 12:09:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340254, encodeId=6e9213402545c, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539625, encodeId=59c51539625c8, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237713, encodeId=5f5d23e713df, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Aug 27 13:29:37 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237385, encodeId=f37e23e385b3, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuNreCBwuEU9I5ich0uE1zdHnicdKjEibG64cgLHSp5sMMFMiatLiaDaSrGOj1jAaDuTZo7vDLDhgRFHt6/0, createdBy=caa52003923, createdName=狼毒花1982, createdTime=Sat Aug 26 13:15:28 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2017-08-27 情途末路

    学习了.获益匪浅!感谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2024539, encodeId=c2872024539cf, content=<a href='/topic/show?id=0219e625d1' target=_blank style='color:#2F92EE;'>#FOXO3a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7625, encryptionId=0219e625d1, topicName=FOXO3a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Thu May 31 15:09:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851510, encodeId=81161851510f4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Oct 28 12:09:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340254, encodeId=6e9213402545c, content=<a href='/topic/show?id=bd5ce780493' target=_blank style='color:#2F92EE;'>#细胞凋亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77804, encryptionId=bd5ce780493, topicName=细胞凋亡)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/EFCEF19303EB52B3F41B30C45995AF2C/100, createdBy=8e712500159, createdName=ms8538335253054589, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539625, encodeId=59c51539625c8, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Mon Aug 28 04:09:00 CST 2017, time=2017-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237713, encodeId=5f5d23e713df, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Sun Aug 27 13:29:37 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=237385, encodeId=f37e23e385b3, content=学习了感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuNreCBwuEU9I5ich0uE1zdHnicdKjEibG64cgLHSp5sMMFMiatLiaDaSrGOj1jAaDuTZo7vDLDhgRFHt6/0, createdBy=caa52003923, createdName=狼毒花1982, createdTime=Sat Aug 26 13:15:28 CST 2017, time=2017-08-26, status=1, ipAttribution=)]
    2017-08-26 狼毒花1982

    学习了感谢分享

    0

相关资讯

Eur Urol:mCRPC患者外周全血中的AR-V7预测治疗反应。

以往的研究已经证明,转移性去势抵抗性前列腺癌(mCRPC)患者循环肿瘤细胞(CTCs)中表达雄激素受体剪接变异体7(AR-V7)可预测其对阿比特龙(abiraterone)或恩杂鲁胺(enzalutamide)的治疗反应较差。

Cancer Res:PADI2调控的瓜氨酸化促进了前列腺癌进展

去雄抵抗性前列腺癌(CRPC)在长期雄激素阻断治疗后的发病仍旧是治疗前列腺癌(PCa)的一个主要障碍。之前的研究表明,肽酰精氨酸脱亚氨酶PADI2在慢性炎症反应疾病中和癌症中具有作用。最近,有研究人员阐释了PADI2是一个雄激素抑制基因,并且在CRPC中表达上调。PADI2的表达对PCa细胞的生存和细胞周期的进展是需要的。在体内和体外试验的雄激素阻断或者去势难治性条件下,PADI2可以促进PCa细

Eur Urol:前列腺癌的保守治疗,观察等待or主动监测?

目前,越来越多的前列腺癌采用保守治疗策略。然而,尚没有对何种随访为最佳随访策略达成共识。因此,研究者欲从预期寿命和生活质量两个方面比较观察等待和主动监测两种随访策略带来的差异。

Cancer Immunol Immunother:DNA编码的抗前列腺特异膜抗原单克隆抗体的新的前列腺癌免疫疗法

前列腺特异膜抗原(PSMA)在恶性肿瘤前列腺细胞中高水平表达,并且很可能是前列腺恶性肿瘤治疗的一个重要的药物靶标。目前已PSMA为治疗靶标的免疫疗法包括肽、细胞、载体或者基于DNA的疫苗以及PSMA特异性单克隆抗体(mAb)被动治疗。传统的mAb免疫治疗具有很多的逻辑和实践限制,包括高额的生产费用和由于短的mAb血清半衰期而导致的频繁剂量输入。最近,有研究人员阐释了一个基于抗体的免疫疗法的新的治疗

Eur Urol:新型血检预测癌症的耐药性,让癌症患者少走冤枉路

当细菌产生抗药性的时候,这些药物就会变得无效。同样,肿瘤细胞也是如此,它们会针对特定的药物逐渐改变,产生耐药性,这对于癌症的治疗时非常关键的,如果医生可以尽早了解这一情况,就可以做出相应的应对措施,来自慕尼黑工业大学的研究人员研发的血液检测可以用来预测晚期前列腺癌患者的耐药性。

CLIN CANCER RES:前列腺癌患者前列腺内阿比特龙水平和SLCO基因变化与病理反应有关

SLCO基因改变会影响细胞类固醇摄取,与前列腺癌结局有关。CYP17A抑制剂阿比特龙也有类固醇结构,SLCO编码的受体可能影响其转运,SLCO基因改变可能会影响细胞内阿比特龙水平并影响其疗效。CLIN CANCER RES近期发表了一篇文章,研究SLCO基因是否对阿比特龙摄取产生影响。